Consun Pharmaceutical Group Limited (stock code: 01681) submitted a Next Day Disclosure Return dated 13 November 2025, reporting that its total issued share capital remained at 847,983,407 shares as of the closing balance on 13 November 2025. No new shares were issued, and no treasury shares were canceled during this period.

From 14 October to 13 November 2025, the company executed a series of share repurchases for cancellation. These transactions involved amounts ranging from 2,000 to over 500,000 shares on individual dates, at prices generally ranging around HKD 14.77 to HKD 15.76 per share. On 13 November 2025, 2,000 shares were repurchased at HKD 15 per share, bringing the repurchase total for that day to HKD 30,000. All repurchased shares are pending official cancellation.

According to the report, the company’s repurchase mandate, granted on 22 May 2025, authorized the repurchase of up to 85,126,334 shares. As of 13 November 2025, 9,898,000 shares had been repurchased, equivalent to approximately 11.6274% of the total issued share capital at the time of the mandate. The disclosure also indicates a 30-day moratorium period from the latest purchase date, up to 13 December 2025, during which the company generally cannot issue new shares without prior approval by the Stock Exchange.